Company intelligence / Profile preview

Citius Oncology

Cranford, New Jersey, United States

Ownership: Public · CTOR
Development stage: Other

Overview

LYMPHIR™ (denileukin diftitox-cxdl) received FDA approval in August 2024 for relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Phase 1 trials in solid tumors (combination with pembrolizumab) show a 27% objective response rate and 33% clinical benefit rate with a median progression-free survival of 57 weeks and a favorable safety profile.

Therapeutic areas: Oncology
Modalities: Recombinant fusion proteinBiologic
Industry: Biotech

Partnerships

Cencora (distribution partnership)Clinical collaborations: University of Minnesota, Masonic Cancer CenterUniversity of Pittsburgh Medical Center, Hillman Cancer Center

Financials

Market cap: $84.6M
Total revenue: $1.5M
Enterprise value: $78.3M

Beyond the preview

Go deeper on Citius Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Citius Oncology.

Explore the full profile